Leslie Dork
Adult Health · Albuquerque, NMNPI 1790703361
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 198 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 198 payments — averaging $35.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Nxstage Medical, Inc.$675
- Vifor Pharma, Inc.$571
- Amgen$536
- Bayer$460
- Novo Nordisk$452
- plus $3K from 19 others
What the payments were for
- Food & beverage$7,017100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 48 | $1,487 |
| Nxstage Medical, Inc. | 9 | $675 |
| Vifor Pharma, Inc. | 18 | $571 |
| Amgen(2 entities) | 8 | $536 |
| Bayer | 10 | $460 |
| Novo Nordisk | 7 | $452 |
| Daiichi Sankyo Inc. | 33 | $431 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $255 |
| Mozarc Medical US LLC | 10 | $239 |
| GSK | 6 | $227 |
| Fresenius USA Marketing, Inc. | 7 | $200 |
| Akebia Therapeutics Inc | 5 | $190 |
| Aurinia Pharma U.S., Inc. | 6 | $164 |
| Abbott | 1 | $154 |
| Otsuka America Pharmaceutical, Inc. | 8 | $151 |
| Ardelyx, Inc. | 2 | $147 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Travere Therapeutics, Inc. | 4 | $124 |
| Calliditas Therapeutics US Inc. | 5 | $100 |
| Lilly USA, LLC | 1 | $96 |
| Baxter Healthcare | 1 | $78 |
| W. L. Gore & Associates, Inc. | 1 | $73 |
| Sanofi | 2 | $45 |
| Ultragenyx Pharmaceutical Inc. | 1 | $26 |
| Shield Therapeutics Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$371
- Kerendia$358
- NXSTAGE SYSTEM ONE$317
- LOKELMA$244
- Tavneos$227
- Veltassa$221
- LIBERTY SELECT CYCLER$208
- FreeStyle Libre$154
- XPHOZAH 30 MG$130
- KRYSTEXXA$124
- Ozempic$124
- Velphoro$122
- Vafseo$111
- PUREFLOW SL$109
- RYBELSUS$104
How this compares
$7,020 in reported general payments places this provider in the 95th percentile of 52 adult health providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 31 | $87,408 |
| Lanthanum Carbonate | 49 | $44,856 |
| AuryxiaFerric Citrate | 15 | $33,430 |
| VeltassaPatiromer Calcium Sorbitex | 20 | $16,294 |
| Sevelamer Carbonate | 72 | $15,689 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $8,859 |
| Calcium Acetate | 17 | $1,422 |
| Furosemide | 61 | $955 |
| Nifedipine ErNifedipine | 11 | $815 |
| Amlodipine Besylate | 76 | $664 |
| Losartan Potassium | 39 | $620 |
| Hydralazine Hcl | 20 | $518 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 30 | $435 |
| Gabapentin | 38 | $419 |
| Carvedilol | 25 | $411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $200 | $87,40831 claims |
| Akebia Therapeutics IncAuryxia | $190 | $33,43015 claims |
| AstraZenecaLokelma | $1,487 | $8,85913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 52 adult health providers in New Mexico.
Other adult health in Albuquerque
- Elizabeth EvansAlbuquerque$9K
- Stephanie MahootyAlbuquerque$6K
- Debra NarcisseAlbuquerque$5K
- Sara RogersAlbuquerque$2K
- Theresa CastlemainAlbuquerque$2K
- Melissa TorresAlbuquerque$2K
- Deborah AnayaAlbuquerque$1K
- Clyde SanchezAlbuquerque$1K
- Sheila MisraAlbuquerque$1K
- Michele HeadAlbuquerque$992
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.